Everett E. Vokes
Impact in
- Otorhinolaryngology top 0.01%
- Head and Neck Cancer Studies
- Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Papers in
-
- Head and Neck Cancer Studies 239
-
- Lung Cancer Diagnosis and Treatment 132
- Lung Cancer Treatments and Mutations 98
- Co-authors
- Ralph R. Weichselbaum (82 shared papers)Daniel J. Haraf (133 shared papers)Waun Ki Hong (7 shared papers)Scott Michael Lippman (6 shared papers)Ezra E.W. Cohen (74 shared papers)Joseph Kamel Salama (38 shared papers)Kerstin M. Stenson (66 shared papers)Tanguy Y. Seiwert (56 shared papers)
- Journals
- Journal of Clinical Oncology (96 papers)Journal of Thoracic Oncology (50 papers)Annals of Oncology (50 papers)International Journal of Radiation Oncology*Biology*Physics (48 papers)Lung Cancer (33 papers)
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Everett E. Vokes
647 papers receiving 61k citations
Everett E. Vokes's Hit Papers
Peers
Comparison fields: 5 of 167
- Otorhinolaryngology 13.9k
- Oncology 22.7k
- Pulmonary and Respiratory Medicine 15.2k
- Pharmacology 1.7k
- Cancer Research 1.9k
Countries citing papers authored by Everett E. Vokes
This map shows the geographic impact of Everett E. Vokes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Everett E. Vokes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Everett E. Vokes more than expected).
Fields of papers citing papers by Everett E. Vokes
This network shows the impact of papers produced by Everett E. Vokes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Everett E. Vokes. The network helps show where Everett E. Vokes may publish in the future.
Co-authors
The 25 scholars most cited alongside Everett E. Vokes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 656 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 8030 |
| 2 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 7161 |
| 3 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2016 | 4071 |
| 4 | Head and Neck Cancer Hit paper breakdown → | 1993 | 1893 |
| 5 | Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Hit paper breakdown → | 2000 | 1197 |
| 6 | Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan Hit paper breakdown → | 2004 | 799 |
| 7 | Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups Hit paper breakdown → | 2008 | 763 |
| 8 | Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Hit paper breakdown → | 2017 | 741 |
| 9 | Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Hit paper breakdown → | 2003 | 683 |
| 10 | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Hit paper breakdown → | 2018 | 640 |
| 11 | Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 634 |
| 12 | UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity Hit paper breakdown → | 2002 | 577 |
| 13 | Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas Hit paper breakdown → | 2014 | 552 |
| 14 | Lung cancer Hit paper breakdown → | 2000 | 548 |
| 15 | Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study Hit paper breakdown → | 2008 | 538 |
| 16 | The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validity Hit paper breakdown → | 1996 | 530 |
| 17 | Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2003 | 529 |
| 18 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 483 |
| 19 | 2004 | 480 | |
| 20 | Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. | 1994 | 442 |
About Everett E. Vokes
Everett E. Vokes is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Pharmacology, having authored 656 papers that have together received 62.9k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (239 papers), Lung Cancer Diagnosis and Treatment (132 papers), Lung Cancer Treatments and Mutations (98 papers), Lung Cancer Research Studies (45 papers), Cancer Immunotherapy and Biomarkers (44 papers), Cancer therapeutics and mechanisms (20 papers), Colorectal Cancer Treatments and Studies (14 papers) and Esophageal Cancer Research and Treatment (13 papers). The work is most often cited by research in Otorhinolaryngology (13.9k citations), Oncology (22.7k citations), Pulmonary and Respiratory Medicine (15.2k citations), Pharmacology (1.7k citations) and Cancer Research (1.9k citations). Everett E. Vokes has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Ralph R. Weichselbaum, Daniel J. Haraf, Waun Ki Hong, Scott Michael Lippman, Ezra E.W. Cohen, Joseph Kamel Salama, Kerstin M. Stenson, Tanguy Y. Seiwert, Mark J. Ratain and Ann M. Mauer. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, International Journal of Radiation Oncology*Biology*Physics and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.